Covid-19 roundup: Inovio nabs $3 million and a development partner for its vaccine that's still on partial hold; Slaoui proposes halving Moderna vaccine doses as distribution lags
With its vaccine candidate finally in Phase II, Inovio is bagging $3 million in a partnership deal with Advaccine Biopharmaceuticals Suzhou to develop and commercialize the candidate in Greater China.
Advaccine and Inovio shook hands on a deal for exclusive rights to develop, manufacture and commercialize the candidate, INO-4800, in Mainland China, Hong Kong, Macao and Taiwan. In addition to $3 million upfront, Advaccine is sweetening the deal with up to $108 million in milestone payments. In return, it stands to earn a “high single-digit percentage” of annual net sales in each region within Greater China. The company is also licensing its plasmid manufacturing process to Inovio, with the right to sublicense to Inovio’s manufacturing partners.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.